Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA)
NCT04746495 · University of Michigan · PHASE4 · withdrawn · last registry update 2023-02-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Issues relate to COVID-19 and staffing challenges, as well as very tight finances.” | – | Registry record, University of Michigan |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against NR3C2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-02-06Phase 3 first posted: University of Erlangen-Nürnberg Medical School, Finerenone 20 MG Oral Tablet + Placebo (NCT06244758)
- 2024-01-12Phase 3 first posted: University Hospital, Caen, Spironolactone (NCT06204640)
- 2023-11-18Phase 3 first posted: Merck Sharp & Dohme LLC, Opevesostat + Abiraterone acetate (NCT06136624)
- 2023-11-18Phase 3 first posted: Merck Sharp & Dohme LLC, Opevesostat + Dexamethasone (NCT06136650)
- 2023-11-18Also stopped (suspended): Rennes University Hospital, Fludrocortisone + Placebo (NCT05001854)
- 2023-10-23Results posted on the registry: Kevin Flanigan, Spironolactone + Prednisolone (NCT03777319)
- 2023-10-23Also stopped (terminated): Kevin Flanigan, Spironolactone + Prednisolone (NCT03777319)
- 2023-10-13Phase 3 first posted: Steno Diabetes Center Copenhagen, Aspirin tablet + Semaglutide (NCT06082063)
- 2023-09-28Phase 3 first posted: The George Institute, Finerenone + Placebo Finerenone (NCT06058585)
- 2023-09-13Phase 3 first posted: Colorado Prevention Center, Finerenone + Placebo (NCT06033950)
- 2023-09-06Phase 3 first posted: Colorado Prevention Center, Finerenone + Empagliflozin (NCT06024746)
- 2023-08-23Phase 3 first posted: Colorado Prevention Center, Finerenone + Placebo (NCT06008197)
- 2023-08-16Phase 3 first posted: Grace Therapeutics Inc., GTX-104 + Nimotop 30 MG Oral Capsule (NCT05995405)
- 2023-08-01Results posted on the registry: University Hospitals Cleveland Medical Center, Spironolactone + Placebo (NCT02169089)
- 2023-06-13Phase 3 first posted: Bayer, Finerenone (NCT05901831)
- 2023-06-02Results posted on the registry: Massachusetts General Hospital, Eplerenone + Placebo (NCT02740179)
- 2023-05-24Also stopped (withdrawn): Mayo Clinic, Carvedilol + Lisinopril (NCT04190433)
- 2023-05-09Phase 3 first posted: October 6 University, Dapagliflozin Farxiga® + Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone® (NCT05849766)
- 2023-05-03Results posted on the registry: Brigham and Women's Hospital, eplerenone + amiloride (NCT02525796)
- 2023-05-01Results posted on the registry: CMP Development, LLC, Digoxin 250 MCG Oral Tablet + Spironolactone 25 mg/ 5 mL S/F Suspension (NCT03909529)
- 2023-03-31Results posted on the registry: Bayer, Finerenone (Kerendia, BAY94-8862) + Placebo (NCT05013008)
- 2023-03-17Also stopped (withdrawn): University of Cincinnati, Eplerenone 50 Mg Tab + Placebo Oral Tablet (NCT03418649)
- 2023-02-24Results posted on the registry: Vifor Pharma, Inc., Patiromer + Placebos (NCT03888066)
- 2023-02-01Also stopped (withdrawn): University of Texas Southwestern Medical Center, Abiraterone acetate + Placebo (NCT03548246)
- 2023-01-09Phase 3 first posted: Universidade do Porto, Dapagliflozin + Spironolactone + Dapagliflozin (NCT05676684)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision